Candel Skyrockets By Triple Digits On A Potential First-In-20-Years Cancer Drug
Shares of Candel Therapeutics skyrocketed Wednesday after the biotech company's prostate cancer treatment succeeded in a Phase 3 study. The post Candel Skyrockets By Triple Digits On A Potential First-In-20-Years Cancer Drug appeared first on Investor's Business Daily.
Shares of Candel Therapeutics skyrocketed Wednesday after the biotech company's prostate cancer treatment succeeded in a Phase 3 study.
The post Candel Skyrockets By Triple Digits On A Potential First-In-20-Years Cancer Drug appeared first on Investor's Business Daily.
iShook Opinion
"iShook Opinion" by Beni E Rachmanov, CEO & Founder of iShook. Explore captivating perspectives on entertainment, lifestyle, and sports at ishookdaily.com. Your go-to for engaging insights.
